This company has been acquired
Coeptis Therapeutics Dirección
Dirección controles de criterios 1/4
Información clave
Dave Mehalick
Chief Executive Officer (CEO)
US$216.5k
Compensación total
| Porcentaje del salario del CEO | 100.0% |
| Permanencia del CEO | 1.6yrs |
| Participación del CEO | 3.5% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 1.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$217k | US$217k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$149k | US$149k | -US$9m |
| Dec 31 2019 | US$147k | US$147k | -US$2m |
Compensación vs. Mercado: Dave's total compensation ($USD216.50K) is below average for companies of similar size in the US market ($USD1.64M).
Compensación vs. Ingresos: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Mehalick (53 yo)
1.6yrs
Permanencia
US$216,500
Compensación
Mr. David Mehalick, also known as Dave, is Chief Business Officer at Sparta Healthcare Acquisition Corp. He is a co-founder of Coeptis Therapeutics Inc. (formerly known as Vinings Holdings Inc.) (formerly...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 1.6yrs | US$216.50k | 3.52% $ 6.0m | |
| Co-Founder | 1.6yrs | US$133.50k | 5.86% $ 10.1m | |
| Co-Founder | 1.6yrs | US$205.50k | 5.86% $ 10.1m | |
| Member of Scientific and Clinical Advisory Board | less than a year | sin datos | sin datos | |
| Member of Scientific and Clinical Advisory Board | less than a year | sin datos | sin datos | |
| Member of Scientific and Clinical Advisory Board | less than a year | sin datos | sin datos |
1.2yrs
Permanencia media
53yo
Promedio de edad
Junta con experiencia: COEP's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.